丙型肝炎病毒治愈后肝硬化再代偿的发生率与临床意义
研究回顾性纳入10个欧洲中心的2570例晚期慢性肝病(ACLD)患者,其中361例为失代偿期肝硬化且经直接抗病毒药物(DAA)治疗获得持续病毒学应答。中位随访8.4年,36.6%的失代偿期患者实现再代偿;再代偿与肝相关死亡和门静脉血栓风险降低独立相关,但肝细胞癌风险未降低。
要点
- 失代偿期肝硬化患者HCV治愈后再代偿发生率为36.6%(132例)。
- 再代偿者肝相关死亡和门静脉血栓风险降低,但肝细胞癌风险未降低。
- 低白蛋白水平和糖尿病与再代偿实现呈负相关。
核心结论
- HCV治愈后再代偿与肝相关死亡和门静脉血栓风险显著降低相关,但与肝细胞癌风险降低无关。
研究设计与样本
- 回顾性纳入10个欧洲中心的2570例晚期慢性肝病(ACLD)患者,其中2209例为代偿期ACLD、361例为失代偿期肝硬化,均经直接抗病毒药物(DAA)治疗获得持续病毒学应答。
主要发现
- 从治疗开始中位随访8.4年,132例(36.6%)失代偿期肝硬化患者实现再代偿。
- 再代偿状态与非再代偿状态相比,肝相关死亡发生率(每100患者年4.2 vs 8.8)和门静脉血栓发生率(每100患者年2.7 vs 5.4)更低,而肝细胞癌发生率仍较高(每100患者年3.9 vs 5.5)。
- 与失代偿期肝硬化相比,实现再代偿独立关联较低的后续肝相关死亡风险(校正风险比0.384;95%置信区间0.225-0.655)和门静脉血栓风险(校正风险比0.421;95%置信区间0.224-0.759),但两者风险仍高于代偿期ACLD。
- 与失代偿期肝硬化相比,肝细胞癌发生率未降低。
- 较低白蛋白水平和糖尿病与实现再代偿呈负相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Baveno VII has proposed criteria for cirrhosis recompensation, but their prognostic significance in decompensated patients cured of hepatitis C virus (HCV) deserves further investigation. Thus, we studied the incidence and impact of recompensation after HCV cure as well as its predictors. METHODS: A total of 2570 patients with advanced chronic liver disease (ACLD) from 10 European centers were retrospectively included, including 2209 and 361 patients with compensated ACLD and decompensated cirrhosis who achieved sustained virologic response to direct-acting antivirals (DAAs). The association between achieving recompensation and clinical outcomes (hepatocellular carcinoma [HCC], portal vein thrombosis [PVT], and [liver-related] death) was investigated. RESULTS: During a median follow-up of 8.4 years from treatment initiation, 132 patients (36.6%) achieved recompensation. Lower albumin levels and diabetes were negatively associated with achieving recompensation. The incidence rates of liver-related death (4.2 vs 8.8 per 100 patient-years) and PVT (2.7 vs 5.4) were substantially lower after recompensation vs in the nonrecompensated state, while HCC incidence remained high (3.9 vs 5.5). Compared with decompensated cirrhosis, achieving recompensation was independently associated with decreased risks of subsequent liver-related death (adjusted hazard ratio, 0.384; 95% confidence interval, 0.225-0.655) and of PVT (adjusted hazard ratio, 0.421; 95% confidence interval, 0.224-0.759), but both risks remained higher than in compensated ACLD. Importantly, HCC incidence was not reduced as compared with decompensated cirrhosis. CONCLUSIONS: Recompensation after HCV cure is associated with substantially decreased risks of (liver-related) mortality and PVT, but not of HCC.
引用
- Semmler G, Lens S, Hidalgo Á, et al. Incidence and Clinical Significance of Recompensation After HCV Cure. Clin Gastroenterol Hepatol. 2025. PMID: 40378989. doi:10.1016/j.cgh.2025.04.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。